eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2024
vol. 26
 
Share:
Send email
Share:
Review paper

Recommendations for the management of Clostridioides difficile infection in adults and comparison with updated ACG, ESCMID and IDSA/SHEA guidelines

Mateusz Piotr Baran
1
,
Jarosław Drobnik
2
,
Mária Belovičová
3, 4, 5
,
Štefánia Moricová
6
,
Piotr Pobrotyn
7

  1. Individual Specialist Medical Practice Mateusz Baran, Wroclaw, Poland
  2. Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland
  3. Faculty of Public Health Studies, Department of Preventive and Clinical Medicine, Slovak Medical University, Bratislava, Slovakia
  4. Internal Clinic for Liver Disease Diagnosis and Treatment, Remedium s.r.o., Bardejov Spa, Slovakia
  5. Slovak Society of Practical Obesitology (SSPO), Bardejov, Slovakia
  6. Faculty of Public Health Studies SZU, Institute of Occupational Health Service, Bratislava, Slovakia
  7. Remedial Specialistic Clinic “Pulsantis Sp. z o.o.”, Wroclaw, Poland
Family Medicine & Primary Care Review 2024; 26(3): 352–356
DOI: https://doi.org/10.5114/fmpcr.2024.142011
Online publish date: 2024/09/30
Article file
- 12 FM&PCR 3 24 - R - Baran - 1517 - Recommendations.pdf  [0.48 MB]
Get citation
 
PlumX metrics:
 
1. Mitchell BG, Gardner A. Mortality and Clostridium difficile infection: a review. Antimicrob Resist Infect Control 2012; 1(20): 1–6.
2. Mirecka A. Zakażenia Clostridium difficile – nadal aktualny problem leczniczy i epidemiologiczny. Przegl Epidemiol 2017; 71(2): 155–164 (in Polish).
3. Jermakow K, Pajączkowska M, Gościniak G. A new risk group of patients with Clostridium difficile associated diarrhoea. Fam Med Prim Care Rev 2013; 15(3): 331–332.
4. Choroby Zakaźne i Zatrucia w Polce w 2021 roku. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Zakład Epidemiologii Chorób Zakaźnych i Nadzoru, Główny Inspektorat Sanitarny, Departament Przeciwepidemiczny i Ochrony Sanitarnej Granic. Warszawa 2021 [cited 27.01.2023]. Available from URL: http://wwwold.pzh.gov.pl/oldpage/epimeld/2021/Ch_2021_Wstepne_dane.pdf/.
5. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021; 73(5): 1029–1044.
6. Prehn J, van, Reigadas E, Vogelzang EH, et al. Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27(Suppl. 2): 1–21.
7. Kelly C R, Fischer M, Allegretti, JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021; 116 (6): 1124–1147.
8. Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe 2016; 40: 95–99.
9. Gayane M, Hryniewicz W, Ozorowski T, et al. Zakażenia Clostridioides (Clostridium) difficile: epidemiologia, diagnostyka, terapia, profilaktyka. Warszawa: Narodowy Instytut Leków; 2018 (in Polish).
10. Sucher A, Biehle L, Smith A, et al. Updated Clinical Practice Guidelines for C difficile Infection in Adults. US Pharm 2021; 46(12): 10–16.
11. Choroby Zakaźne i Zatrucia w Polce w 2018 roku. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Zakład Epidemiologii Chorób Zakaźnych i Nadzoru, Główny Inspektorat Sanitarny, Departament Przeciwepidemiczny i Ochrony Sanitarnej Granic. Warszawa 2019 [cited 27.01.2023]. Available from URL: http://wwwold.pzh.gov.pl/oldpage/epimeld/2018/Ch_2018.pdf/ (in Polish).
12. Choroby Zakaźne i Zatrucia w Polce w 2019 roku. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Zakład Epidemiologii Chorób Zakaźnych i Nadzoru, Główny Inspektorat Sanitarny, Departament Przeciwepidemiczny i Ochrony Sanitarnej Granic. Warszawa 2020 [cited 27.01.2023]. Available from URL: http://wwwold.pzh.gov.pl/oldpage/epimeld/2019/Ch_2019.pdf/ (in Polish).
13. Choroby Zakaźne i Zatrucia w Polce w 2020 roku. Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny, Zakład Epidemiologii Chorób Zakaźnych i Nadzoru, Główny Inspektorat Sanitarny, Departament Przeciwepidemiczny i Ochrony Sanitarnej Granic. Warszawa 2021 [cited 27.01.2023]. Available from URL: http://wwwold.pzh.gov.pl/oldpage/epimeld/2020/Ch_2020.pdf/ (in Polish).
14. Bignardi G. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1–15.
15. Mertz D, Frei R, Plagge H, et al. Stronger correlation between antibiotic use and incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only. Eur J Clin Micrbiol Infect Dis 2010; 29(12): 1575–1578.
16. Ma J, Dubberke E. Postępowanie w zakażeniu Clostridioides (Clostridium) difficile u dorosłych. Podsumowanie wytycznych Infectious Diseases Society of America i Society for Hospital Epidemiology of America 2017. Med Prakt 2019; 3: 54–57 (in Polish).
17. Mehlich A, Górska S, Gamian A, et al. Wybrane aspekty zakażeń Clostridium difficile. Postepy Hig i Med Dosw 2015; 69: 598–611 (in Polish).
18. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66(7): 1–48.
19. Cohen S, Gerding D, Jonson S, et al. Clinical Practice Guidelines for Clostridium difficile infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431–455.
20. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364(5): 422–431.
21. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12(4): 281–289.
22. Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 2018; 18(3): 296–307.
23. Mikamo H, Tateda K, Yanagihara K, et al. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. J Infect Chemother 2018; 24(9): 744–752.
24. Wankomycyna. Indeks leków medycyny praktycznej [cited 27.01.2023]. Available from URL: http://indeks.mp.pl/leki/desc.php?id=819/ (in Polish).
25. Zinplava (bezlotoxumab) package insert. Whitehouse Station (NJ): Merck & Co, Inc; 2016.
26. Zinplava. Aneks 1. Charakterystyka produktu leczniczego [cited 27.01.2023]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/zinplava-epar-product-information_pl.pdf/ (in Polish).
27. Gergely Szabo B, Kadar B, Szidonia Lenart K, et al. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect 2016; 22: 990–995.
28. Bielec D, Stempkowska J, Markiewicz-Zięba M. Postępy w leczeniu zakażenia Clostridium difficile. Postepy Nauk Med 2014; 27; 11: 770–775 (in Polish).
29. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245: 267–272.
30. Poylin V, Hawkins AT, Bhama AR, et al. Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum 2021; 64(6): 650–668.
31. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage an alternative to total abdominal colectomy for the treatment of severe complicated Clostridium difficile associated disease. Ann Surg 2011; 254: 423–429.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.